Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,061 stopped studies mapped to Carcinoma of Unknown Primary and descendants · 91% state a reason
Over the 2,061 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02454517 | Diet and Exercise Program to Promote Weight Loss and Improve Health in Men With Low- or…(PALS) | N/A | terminated | May 27, 2015 | Fred Hutchinson Cancer Center | Terminated due to insufficient funding | Funding |
| NCT02923531 | Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma | Phase 1 / Phase 2 | terminated | Oct 4, 2016 | X4 Pharmaceuticals | Due to low enrollment, the study was terminated early. | Enrollment / accrual |
| NCT05472220 | Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive… | Phase 1 | withdrawn | Jul 25, 2022 | Pamela Munster | Sponsor funding | Funding |
| NCT04147143 | CaboCHECK - Cabozantinib in Adult Patients With Advanced Renal Cell Carcinoma Following… | — | terminated | Oct 31, 2019 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Due to insufficient recruitment rate, recruitmend has been terminated after inclusion of 56 patients | Enrollment / accrual |
| NCT04941365 | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy(SERPENTINE) | N/A | withdrawn | Jun 28, 2021 | Institut du Cancer de Montpellier - Val d'Aurelle | please refer to NCT05621837 | Other (stated, no rule matched) |
| NCT03387514 | Functional Microscale Organotypic Assays to Predict Patient Response to Anti-Angiogenesis…(UW17104) | Phase 2 | terminated | Jan 2, 2018 | University of Wisconsin, Madison | Termination of funding due to low subject enrollment due to change in standard of care systemic… | Enrollment / accrual |
| NCT01433016 | Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI(OBT for HCC) | Phase 2 | terminated | Sep 13, 2011 | Meridian Bioscience, Inc. | Due to budgetary issues, the company has decided to focus on other applications at this stage. | Funding |
| NCT04291950 | Epigenetics of TNBC in Overweight and Obese Hispanic & Non-Hispanic White Women | — | withdrawn | Mar 2, 2020 | University of Arizona | Principal investigator is moving to a new institution. Study is closing. | Investigator |
| NCT04453046 | Hemopurifier Plus Pembrolizumab in Head and Neck Cancer | N/A | terminated | Jul 1, 2020 | Aethlon Medical Inc. | Lack of Eligible subjects at study site | Other (stated, no rule matched) |
| NCT05393635 | ITIL-168 in Advanced Solid Tumors(DELTA-2) | Phase 1 | withdrawn | May 26, 2022 | Instil Bio | business decision | Sponsor / business decision |
| NCT01381211 | Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of…(TRACE) | Phase 2 | terminated | Jun 27, 2011 | University Hospital, Ghent | based on interim analysis results | Efficacy / futility |
| NCT04642690 | Nitrates and IL-8 in Barrett's Esophagus | — | terminated | Nov 24, 2020 | Mayo Clinic | could not collect adequate samples | Other (stated, no rule matched) |
| NCT05062174 | Breast Cancer BRCA1 Carriers: a Pilot Study | — | withdrawn | Sep 30, 2021 | Indiana University | PI decision to cancel research | Other (stated, no rule matched) |
| NCT03781960 | Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma | Phase 2 | terminated | Dec 20, 2018 | Abramson Cancer Center at Penn Medicine | Safety letter from sponsor | Safety / toxicity |
| NCT04178642 | The Impact on Hepatic Recurrence After Adjuvant Chemotherapy With Intraarterial Infusion…(LIDA-ADJ) | Phase 2 | withdrawn | Nov 26, 2019 | University Hospital, Montpellier | no participants enrolled | Enrollment / accrual |
| NCT05327738 | Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of… | Phase 2 | withdrawn | Apr 14, 2022 | OHSU Knight Cancer Institute | Due to inadequate funding. This trial may open as a new clinical trial at a later date, pending… | Funding |
| NCT05219578 | RTX-224 Monotherapy in Patients With Solid Tumors | Phase 1 / Phase 2 | terminated | Feb 2, 2022 | Rubius Therapeutics | The Sponsor terminated study after dosing 2 dose groups (7 pts) and closed trial on 11/30/22.… | Other (stated, no rule matched) |
| NCT05380557 | ARTEMIS: Study of Patients With Early Stage Pancreatic Cancer Who Have Undergone Genetic…(ARTEMIS) | — | terminated | May 19, 2022 | Invitae Corporation | Low site engagement and accrual | Enrollment / accrual |
| NCT03513042 | Early Response Evaluation of Proton Therapy by PET-imaging in Squamous Cell Carcinoma…(ERM-PT-HNSCC) | — | terminated | May 1, 2018 | Leiden University Medical Center | Inclusionrate dropped due to changes in clinical process | Other (stated, no rule matched) |
| NCT04762225 | RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors… | Phase 1 | terminated | Feb 21, 2021 | Repertoire Immune Medicines | Development program terminated | Other (stated, no rule matched) |
| NCT05061940 | This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status… | — | terminated | Sep 30, 2021 | Repertoire Immune Medicines | Development program terminated | Other (stated, no rule matched) |
| NCT05233696 | Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive… | Phase 2 | withdrawn | Feb 10, 2022 | University of Colorado, Denver | Low Accrual | Enrollment / accrual |
| NCT05325164 | Methadone for 'Adenocarcinopathic' Pain Treatment(METHADOPT) | Phase 3 | withdrawn | Apr 13, 2022 | Ottawa Hospital Research Institute | Trial not started; change in Sponsor and Principal Investigator, trial to be registered again by… | Investigator |
| NCT04400903 | Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer | — | terminated | May 26, 2020 | OHSU Knight Cancer Institute | Slow accrual | Enrollment / accrual |
| NCT04268693 | Bisphenol and Phthalate Exposures in Triple Negative Breast Cancer(EDC-TNBC) | — | withdrawn | Feb 13, 2020 | George Washington University | Study never initiated due to COVID pandemic, staffing changes | COVID-19 / pandemic |
| NCT05093387 | SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative… | Phase 1 | withdrawn | Oct 26, 2021 | Northwestern University | funding issues and pharmacy preparation for the drug | Funding |
| NCT03506048 | Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive… | Phase 2 | terminated | Apr 23, 2018 | Emory University | Study has been abandoned for lack of accrual | Enrollment / accrual |
| NCT02437916 | Safety Study of AMG 228 to Treat Solid Tumors | Phase 1 | terminated | May 8, 2015 | Amgen | not stated | Not stated |
| NCT02124902 | Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and… | Phase 2 | terminated | Apr 28, 2014 | Washington University School of Medicine | Insufficient funding/staff | Funding |
| NCT02474173 | Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer | Phase 1 | terminated | Jun 17, 2015 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT04242173 | Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC | Phase 2 | terminated | Jan 27, 2020 | H. Lee Moffitt Cancer Center and Research Institute | Lack of Interest | Other (stated, no rule matched) |
| NCT01167374 | Carbon Ion Radiotherapy for Hepatocellular Carcinoma(PROMETHEUS-01) | N/A | terminated | Jul 22, 2010 | University Hospital Heidelberg | Slow recruitment rate | Enrollment / accrual |
| NCT03579472 | M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast… | Phase 1 | terminated | Jul 6, 2018 | M.D. Anderson Cancer Center | Due to the fact that the sponsor decided not to move forward with the development of M7824 | Sponsor / business decision |
| NCT01266018 | Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung… | Phase 2 | terminated | Dec 24, 2010 | Ludwig Institute for Cancer Research | Lack of efficacy in Cohort 2; slow enrollment in Cohort 1 | Efficacy / futility |
| NCT03693846 | Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors | Phase 2 | terminated | Oct 3, 2018 | Abramson Cancer Center at Penn Medicine | Terminated due to slow enrollment and lack of efficacy | Efficacy / futility |
| NCT02415036 | Melphalan for Use With the Hepatic Delivery System Treatment in Patients With… | Phase 2 | terminated | Apr 14, 2015 | Delcath Systems Inc. | Limited enrollment | Enrollment / accrual |
| NCT05093608 | SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced… | Phase 1 | terminated | Oct 26, 2021 | H. Lee Moffitt Cancer Center and Research Institute | Loss of funding | Funding |
| NCT00520533 | Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced… | Phase 1 | terminated | Aug 24, 2007 | Ludwig Institute for Cancer Research | Closed prematurely due to toxicity | Safety / toxicity |
| NCT01891695 | OPSCC N0 Nodal Control With Reduced IMRT | N/A | terminated | Jul 3, 2013 | Paul W. Read, MD | Study had very specific inclusion/exclusion criteria and difficult to recruit | Enrollment / accrual |
| NCT04022876 | A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects… | Phase 1 | terminated | Jul 17, 2019 | Aileron Therapeutics, Inc. | With a favorable safety profile the difference between treatment groups for the primary composite… | Safety / toxicity |
| NCT01727336 | Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma | Phase 2 | terminated | Nov 16, 2012 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | The study was terminated by the sponsor following unblinding of the Progression Free Survival… | Other (stated, no rule matched) |
| NCT03781778 | Pilot Trial of Resistant Starch in Stage I-III Colorectal Cancer Survivors | Phase 2 | terminated | Dec 20, 2018 | Fred Hutchinson Cancer Center | Terminated due to expiration of funding | Funding |
| NCT03723915 | Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer | Phase 2 | terminated | Oct 30, 2018 | Northwestern University | The total accrual goal of 34 patients was not met. Stage 1 of the study did not meet the interim… | Efficacy / futility |
| NCT04861948 | IBI188 Combination Therapy in Solid Tumors | Phase 1 | terminated | Apr 27, 2021 | Innovent Biologics (Suzhou) Co. Ltd. | No signs of efficacy in solid tumors | Efficacy / futility |
| NCT01174199 | Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer | Phase 1 | terminated | Aug 3, 2010 | Roswell Park Cancer Institute | no value in finding efficacy | Efficacy / futility |
| NCT02295540 | Hypofractionated Radiation Therapy Followed by Surgery in Treating Patients With Advanced… | N/A | withdrawn | Nov 20, 2014 | Rutgers, The State University of New Jersey | slow accrual | Enrollment / accrual |
| NCT02943733 | Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs | Phase 1 | terminated | Oct 25, 2016 | University of Wisconsin, Madison | closed per sponsor request, for slow enrollment | Enrollment / accrual |
| NCT04985825 | Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma(I-PACE) | Phase 2 | withdrawn | Aug 2, 2021 | Pega-One S.A.S. | Business decision | Sponsor / business decision |
| NCT04876378 | Impact of Breast Cancer Treatment on Joint Health, Cartilage Composition, and Bone… | — | terminated | May 6, 2021 | University of California, San Francisco | Funding | Funding |
| NCT04985136 | A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice… | Phase 3 | terminated | Aug 2, 2021 | Jiangsu HengRui Medicine Co., Ltd. | Sponsor R \& D Strategy Adjustment | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Jan 4, 2023source: clinicaltrials